Long-term Effects of a 3-month Pedometer-based Program to Enhance Physical Activity in Patients With Severe COPD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03114241|
Recruitment Status : Recruiting
First Posted : April 14, 2017
Last Update Posted : October 19, 2018
|Condition or disease||Intervention/treatment||Phase|
|COPD||Behavioral: Intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||74 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Eligible patients will be randomized 1:1 to one of the two groups: conventional care group or intervention group. No minimization procedures are used.|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Long-term Effects of a 3-month Pedometer-based Program to Enhance Physical Activity in Patients With Severe COPD|
|Actual Study Start Date :||May 2, 2017|
|Estimated Primary Completion Date :||August 31, 2019|
|Estimated Study Completion Date :||August 31, 2019|
Active Comparator: Intervention
An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
No Intervention: Control
- Difference between the changes in number of steps per day (assessed over one week) from baseline to 12 months in the intervention group compared to controls. [ Time Frame: 12 months ]At visits, the number of steps per day will be assessed by a multisensory band (SenseWear Pro™; Bodymedia Inc., Pittsburgh, PA, USA) which will be worn on the upper left arm for 7 consecutive days.
- Assessment of endothelial function by flow-mediated dilatation [ Time Frame: 12 months ]Flow-mediated dilatation measurements will be performed by ultrasonography of the brachial artery with a high-frequency (10.0-MHz) ultrasound-scanning probe proximal to the antecubital fossa. Flow mediated dilatation will be assessed by percent of baseline Diameter.
- Number of COPD exacerbations [ Time Frame: 12 months ]The number of COPD exacerbations in the previous year and during the study period will be assessed
- Height [ Time Frame: 12 months ]Body height (meter)
- Weight [ Time Frame: months ]Body weight (Kilogram)
- Blood pressure [ Time Frame: 12 months ]Blood pressure (mmHg) is measured in triplicate separated by 1-minute intervals after resting in supine position for 5 minutes in a quiet room with a validated, semi-automated oscillometric device
- Herat rate [ Time Frame: 12 months ]Heart rate (bpm) is measured in triplicate separated by 1-minute intervals after resting in supine position for 5 minutes in a quiet room.
- Blood gas analysis [ Time Frame: 12 months ]Daytime blood gas analysis will be performed without supplemental oxygen and immediately analysed with a commercially available blood gas analyser (ABL90 Radiometer Copenhagen. Arterial pressure of oxygen (PaO2) and carbon dioxide (PaCO2) will be assessed. Further, oxygen saturation (SaO2) will be determined.
- Questionnaire: Hospital Anxiety and Depression Scale (HADS): [ Time Frame: 12 months ]The questionnaire is especially designed for patients with physical impairment and assesses their symptoms of anxiety and depression. There are 7 items for each domain (anxiety and depression). Agreement on statements is expressed on a scale from 0 to 3 and domain scores are calculated by summing up the scores for the 7 items resulting in scores from 0 (no anxiety/depression) to 21 (depression/anxiety very likely).
- Questionnaire: COPD Assessment Test (CAT) [ Time Frame: 12 months ]The test is designed to measure the impact of COPD on the patients' life and how this changes over time. The test includes 8 questions each with a scale from 0 to 5. The eight questions not only address respiratory or chest-related symptoms such as cough or sensation of mucus accumulation or chest tightness, but also more general complaints such as disturbances in sleep or decreased energy levels and daily limitations resulting from the disease. The total score will be assessed.
- Questionnaire: Physical acitivity questionnaire [ Time Frame: 12 months ]The questionnaire includes items about household activities, sport, and leisure time activities. The time and intensity spent at different physical acitivty levels will be assessed.
- Questionnaire: Short-Form 36 (SF-36) Questionnaire [ Time Frame: 12 months ]The SF-36 consists of eight scaled scores that are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The categories are vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health
- Comorbidities [ Time Frame: 12 months ]The number and type of medical comorbidities will be assessed by interview.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03114241
|Contact: Christian F Clarenbach, MDemail@example.com|
|Contact: Noriane Sievi, MScfirstname.lastname@example.org|
|University Hospital Zurich||Recruiting|
|Zürich, Zurich, Switzerland, 8091|
|Contact: Christian F Clarenbach, MD +41 44 255 17 12 email@example.com|
|Contact: Noriane A Sievi, MSc +41 44 255 98 15 firstname.lastname@example.org|
|Principal Investigator:||Christian F Clarenbach, MD||University of Zurich|